Next-generation, selective kinase medicines
Our proprietary scientific platform enables us to rapidly and reproducibly design medicines that selectively target kinase drivers of disease, enabling improved potency, less off-target activity and an increased probability of clinical success.
Discovered by Blueprint Medicines, pralsetinib is an investigational RET inhibitor for certain RET-altered solid tumors.
Cometriq® (cabozantinib), an FDA-approved multi-kinase inhibitor for advanced medullary thyroid cancer (MTC)
Caprelsa® (vandetanib), an FDA-approved multi-kinase inhibitor for advanced MTC
Kinome illustrations reproduced courtesy of Cell Signaling Technology, Inc. (CSTI).
A focused strategy
Our research focuses on kinase targets where we believe our technology can lead to meaningful improvements in treatment.
Well-recognized kinases that are difficult to target with existing technologies
Mutant kinases that have become resistant to current treatments
New targets identified with our computational and cell biology expertise